BioSpace News Archive

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of its common stock in an underwritten public offering.

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced the publication in Nature of preclinical research with live biotherapeutic products designed using the Company’s Synthetic Biotic™ platform.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on October 26, 2021, at 3:00 p.m. ET it will host a key opinion leader (KOL) webinar on ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with various complement mediated diseases.

Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, announced Blake Aftab, Ph.D., has been promoted to the position of Senior Vice President and Chief Scientific Officer.

Inogen, Inc. (NASDAQ: INGN), (“Inogen” or “the Company”), today announced that Stanislav Glezer, MD has been appointed to the role of Chief Technology Officer responsible for R&D and Engineering, Medical Affairs, and Regulatory Affairs.

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), announced today that pre-clinical data that support anti-tumor activity of UCARTMESO will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021).

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, today announced that it will report financial results for the third quarter of 2021 after the market close on Wednesday, November 3, 2021.

Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced the pricing of an underwritten public offering of 13,207,547 shares of its common stock at a public offering price of $26.50 per share.